




Seminar

Investing in Biotech in Europe from Seed to Exit: Latest Trends

Invitation

May 3, 2018
Munich



Next

Print

Exit

Seminar

Investing in Biotech in Europe from Seed to Exit: Latest Trends

We cordially invite you to our seminar

“Investing in Biotech in Europe from Seed to Exit: Latest Trends”

During the seminar we will handle topics such as:

- Pitfalls when launching a biotech venture out of university, in-licensing IP and Know-how from the tech transfer office, suitable deal terms with institutional VC investors, managing the conflict of interest of the spin-off as a university scientist and shareholder of the venture business.
- Accelerated exit by an structured M&A deal with big pharma – taking advantage of crossover financing – managing multiple tracks to secure funding – seamless work streams towards IPO or trade sale.

The number of participants is limited. Please ensure your place.

Agenda

1:30 pm **Registration**

2:00 pm **Opening remarks**

Dr. Constanze Ulmer-Eilfort, Baker McKenzie

Part 1: The New Spin on University Spin-offs

2:30 pm **Presentation**

Dos and Don'ts in license agreements with universities and tech transfer offices

Fabian Böttger, Baker McKenzie

Merger control filing obligations in non-revenue start-up company transactions

Dr. Christian Burholt, Baker McKenzie



Fabian Böttger, LLM.
Senior Associate, IP Practice Group
Member Healthcare Industry Group
Baker McKenzie, Munich



Dr. Michael Brandkamp
Managing Director
High-Tech Gründerfonds



Julia Braun, LLM.
Counsel, Corporate Practice Group
Member Healthcare Industry Group
Baker McKenzie, Munich



Dr. Christian Burholt, LL.M.
Partner, Antitrust Practice Group
Member Healthcare Industry Group
Baker McKenzie, Berlin



Fiona Carlin
Partner, Head of the Global Antitrust Group
Member Healthcare Industry Group
Baker McKenzie, Brussels



Dr. J. Donald (Don) deBethizy
Chairman Albumedix Ltd, President of White City Consulting ApS, Chairman Saniona AB, Board Member argenx N.V., Board Member Newron Pharmaceuticals S.P.A., Chairman Supervisory Board Noxxon Pharma N.V., Former chairman of the board of Rigontec GmbH, Former CEO and president of Santaris Pharama S/A



Dr. Franz-Werner Haas, LLD, LL.M.
Member of the Board/CCO
CureVac AG

Speakers (sorted alphabetically)

Next

Back

Print

Exit

Seminar

Investing in Biotech in Europe from Seed to Exit: Latest Trends

3:00 pm **Panel 1**

Avoiding pitfalls when launching university spin-offs, structure considerations and typical deal terms with institutional VC Investors and tech transfer offices, managing the conflict of interest of the spin-off as a university scientist and shareholder of the venture

Panelists:

Dr. Michael Brandkamp, High-Tech Gründerfonds

Dr. Karin Kleinhans, LSP – Life Sciences Partners

Dr. Holger N. Reithinger, Forbion

Dr. Christian Stein, Ascenion GmbH

Prof. Dr. med. Dr. Thomas Thum, Cardior Pharmaceuticals GmbH

Moderator:

Julia Braun, Baker McKenzie

3:45 pm **Coffee break**

Part 2: Multiple tracks – simultaneously handling of the alternative exit routes as a biotech company

4:00 pm **Presentation**

Crossover financing rounds / IPO preparation, listing venue, analyst coverage, stalled IPO risks, key issues in structured M&A deals with big pharma

Dr. Ulrich Kinzel, goetzpartners securities Ltd.



Prof. Dr. med. Gunter Hartmann
Director Institute of Clinical Chemistry and Clinical Pharmacology, Speaker of the DFG Excellence Cluster ImmunoSensation, Vice-Dean of Research of the Medical Faculty, Co-Founder Rigontec GmbH, University Hospital, University of Bonn



Berthold A. Hummel
Partner, Corporate Practice Group
Member Healthcare Industry Group
Baker McKenzie, Munich



Dr. Ulrich Kinzel
Managing Director with goetzpartners securities Ltd., Head of goetzpartners Healthcare Industry Group



Dr. Karin Kleinhans
Associate
LSP – Life Sciences Partners



Dr. Matthias Kromayer
Member of the Board/General Partner
MIG AG



Dr. Holger N. Reithinger
General Partner
Forbion



Dr. Joachim (JR) Rothe
General Partner
LSP – Life Sciences Partners

Next

Back

Print

Exit

Seminar

Investing in Biotech in Europe from Seed to Exit: Latest Trends

4:30 pm **Presentation**

Retaining corporate finance and auctioned sale process, timing and access to due diligence information, scope and jurisdiction of the share purchase agreement, purchase price adjustment mechanism, equity bridge, greater importance of the milestone legal language, structuring liability and indemnity regime for sellers, integration issues as part of the SPA negotiation

Berthold A. Hummel, Baker McKenzie

5:00 pm **Panel 2**

What makes a successful biotech company exit, sharing experience in complex M&A transactions, considerations for initial public offering or trade sale to big pharma as financing and/or (early) exit route, communicating in a dual or triple track process, IPO experience from a VC investor perspective, alternative route as stand alone biotech company, managing conflict of interest as board member and institutional shareholder representative

Panelists:

Dr. J. Donald (Don) deBethizy, Albumedix Ltd

Dr. Franz-Werner Haas, CureVac AG

Prof. Dr. med. Gunter Hartmann, Co-Founder Rigontec GmbH

Dr. Joachim (JR) Rothe, LSP – Life Sciences Partners

Dr. Matthias Kromayer, MIG AG

Moderator:

Dr. Claudia Ulbrich, ulbrich&partner management consulting

5:45 pm **Closing remarks**

Fiona Carlin, Baker McKenzie

6:00 pm **Get-together**



Dr. Christian Stein
Managing Director
Ascenion GmbH



Prof. Dr. med. Dr. Thomas Thum
Founder Cardior Pharmaceuticals GmbH
Professor/Institute Director at the
Medical University Hannover



Dr. Claudia Ulbrich
Managing Partner
ulbrich & partner management consulting



Dr. Constanze Ulmer-Eilfort, LL.M.
Partner, Global Executive Committee
Member Healthcare Industry Group
Baker McKenzie, Munich

**When: May 3, 2018
1:30 to 7:00 pm**

Where: Baker McKenzie
Theatinerstrasse 23
80333 Munich, Germany

[**Map**](#)

Next

Back

Print

Exit

Registration form

Seminar

Investing in Biotech in Europe from Seed to Exit:
Latest Trends

Munich | May 3, 2018

If you wish to attend the seminar,
please send the reply card until April 27, 2018
to clientevents@bakermckenzie.com

Your contact

Mag. Verena Asen
Senior Manager Marketing
Schottenring 25 · 1010 Vienna
Tel.: +43 1 2 42 50 523 · Fax: +43 1 2 42 50 600
clientevents@bakermckenzie.com

- Yes, I would like to attend the seminar.
- Unfortunately, I cannot participate.

Send

Name

Position

Company

Address

Telephone

Yes, I would like to receive more information on other Baker McKenzie events.

Please keep me updated on the following topics:

E-Mail

Please remove my contact details from your database.

Back

Print

Exit